Welcome to our dedicated page for Rallybio SEC filings (Ticker: RLYB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rallybio Corporation (RLYB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company focused on severe and rare diseases, Rallybio uses its Forms 10-K, 10-Q, and 8-K to report financial performance, pipeline developments, and material corporate events.
Rallybio’s filings include quarterly and annual reports that detail collaboration and license revenue, research and development expenses, general and administrative expenses, net income or loss, and cash, cash equivalents, and marketable securities. These reports also describe the status of key programs such as RLYB116, a differentiated C5 inhibitor in a confirmatory PK/PD Phase 1 study, and preclinical assets like RLYB332 for diseases of iron overload. Disclosures about discontinued programs, such as RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), appear in these documents and related press releases.
Current Reports on Form 8-K provide timely updates on material events, including quarterly financial results, the sale of Rallybio’s interest in the ENPP1 inhibitor program REV102 to Recursion Pharmaceuticals, and Nasdaq listing matters. An August 2025 8-K, for example, describes the transfer of Rallybio’s listing to the Nasdaq Capital Market and the additional compliance period granted to regain the minimum bid price requirement.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand changes in Rallybio’s financial position, pipeline priorities, and corporate transactions. Users can review real-time updates from EDGAR, examine historical 10-K and 10-Q reports, and track 8-K disclosures related to financing, collaborations, and listing compliance, all in one place.
Rallybio Corporation has entered into a merger agreement to acquire Candid Therapeutics, with Candid surviving as a wholly owned subsidiary and Rallybio to be renamed Candid Therapeutics, Inc. At the Effective Time, each share of Candid capital stock will convert into the right to receive approximately 0.0716 shares of Rallybio Common Stock (the Exchange Ratio), assuming a 1-for-2.5 reverse stock split and subject to adjustments.
Concurrently, Candid entered a subscription agreement for a $505.5 million financing (the Concurrent Financing). On a pro forma, fully diluted basis (using disclosed assumptions), Candid equityholders are expected to own ~57.55% of the combined company, Concurrent Financing investors ~38.80%, and pre-Merger Rallybio equityholders ~3.65%. The Exchange Ratio and ownership outcomes assume a Rallybio valuation of $47.5 million (assuming Rallybio Net Cash of $37.5 million) and a fixed Candid valuation of $750.0 million. The Merger is conditioned on stockholder approvals, customary closing conditions, regulatory clearances including HSR, and satisfaction or waiver of other specified conditions.
Rallybio Corporation files its annual report describing a clinical-stage rare disease pipeline and a planned all‑stock merger with Candid Therapeutics. The deal includes a $505.5 million concurrent financing into Candid and complex exchange ratios that will significantly reshape ownership.
On a pro forma fully diluted basis, Candid equityholders are expected to own about 57.55% of the combined company, Rallybio pre‑merger holders about 3.65%, and concurrent financing investors about 38.80%, subject to net cash and other adjustments. Existing Rallybio holders will also receive contingent value rights tied to future monetization of Rallybio’s legacy assets, including payments from Recursion under a 2025 ENPP1 program sale.
The report highlights lead C5 inhibitor RLYB116, which showed complete and sustained complement inhibition in a 2025 Phase 1 multiple‑ascending‑dose trial, and preclinical iron‑overload antibody RLYB332. Rallybio notes prior collaborations, asset sales, and an ongoing strategic shift toward the Candid autoimmune T‑cell engager platform while winding down certain general and administrative functions.
FMR LLC filed an initial ownership report for Rallybio Corp, disclosing indirect beneficial ownership of 211,798 shares of Common Stock. These shares are held through F-Prime Capital Partners Life Sciences Fund VI LP. The filing records this position as a holding rather than a new purchase or sale.
FMR LLC reports beneficial ownership of 561,798 shares of Rallybio Corp common stock, representing 10.6% of the class. The Schedule 13G/A lists sole dispositive and sole voting power for FMR LLC over these shares and notes certain other persons may have rights to dividends or sale proceeds.
RALLYBIO CORP ownership disclosure: FMR LLC reports beneficial ownership of 372,827 shares of common stock, equal to 7.1% of the class as of 03/02/2026. The filing states FMR LLC has sole voting and dispositive power over these 372,827 shares.
The filing also attributes dispositive power over the same 372,827 shares to Abigail P. Johnson. Signatures are dated 03/05/2026 and an Exhibit 99 is referenced for a 13d-1(k)(1) agreement.
Rallybio Corp received an updated Schedule 13D from TPG-affiliated entities showing continued beneficial ownership of 378,551 shares of common stock, or about 7.2% of the 5,289,675 shares outstanding as of February 26, 2026. The shares are held through The Rise Fund Rascal, L.P., and may be deemed beneficially owned by TPG GP A, LLC, James G. Coulter and Jon Winkelried, who each report no sole voting or dispositive power but shared power over these shares.
The filing explains that on March 1, 2026, Rallybio agreed to acquire Candid Therapeutics, Inc. via a merger in which Candid will become a wholly owned subsidiary. In connection with this merger agreement, Rise Fund Rascal entered into a support agreement committing to vote all of its Rallybio shares in favor of approving the merger and related transactions, vote against competing proposals or third‑party acquisition offers, and refrain from soliciting or negotiating alternative acquisition proposals in its capacity as a stockholder.
The reporting persons state they currently have no additional specific plans relating to corporate actions such as further mergers, asset sales, or board changes, but reserve the right to review their position, suggest changes to Rallybio’s operations, management, or capital structure, and potentially pursue actions that could affect control or ownership structure in the future.
Rallybio Corporation entered into a definitive Merger Agreement with Candid Therapeutics and Rallybio’s wholly owned subsidiary to merge Merger Sub into Candid, making Candid a wholly owned subsidiary of Rallybio. Concurrent with signing, Candid secured a Concurrent Financing for $505.5 million. The Merger’s exchange formula contemplates pro forma ownership of approximately 57.55% for pre‑Merger Candid equityholders, 3.65% for pre‑Merger Rallybio equityholders and 38.80% for Concurrent Financing investors (assuming the $505.5 million financing and specified cash and valuation assumptions, including a Rallybio valuation of $47.5 million and a Candid valuation of $750.0 million). The transaction contemplates a tax‑free reorganization, a Form S-4 filing and stockholder votes on issuance thresholds, a reverse split (previously effective at 1‑for‑8), an Authorized Share Increase, equity plan approvals and CVRs for certain pre‑closing Rallybio holders. Closing is subject to customary conditions, approvals, determination of Rallybio net cash and HSR clearance.
Rallybio Corporation agreed to merge with clinical-stage biotech Candid Therapeutics in a stock deal that will leave Candid’s investors owning the vast majority of the combined company. A concurrent private financing will provide $505.5 million of new capital to support Candid’s T‑cell engager pipeline for autoimmune diseases.
Based on agreed valuations and assuming Rallybio net cash of $37.5 million, pre‑transaction Rallybio holders are expected to own about 3.65% of the combined company, while Candid holders (including new investors) will own about 96.35%. The new entity will be renamed Candid Therapeutics, Inc. and is expected to trade on Nasdaq under ticker “CDRX”.
Rallybio stockholders will receive contingent value rights tied to cash proceeds from dispositions of Rallybio’s legacy assets. Closing requires shareholder approvals, an effective Form S‑4, completion of at least $200 million of the financing, Nasdaq listing approvals and antitrust clearance, among other customary conditions. Rallybio also reports it has regained compliance with Nasdaq’s minimum bid price rule following a 1‑for‑8 reverse stock split.
Rallybio Corp’s major venture backer 5AM Ventures and related entities have updated their ownership positions in the company’s common stock. The amendment shows 5AM Ventures V, L.P. holding 135,319 shares, or 2.6% of Rallybio’s outstanding common stock, and 5AM Opportunities I, L.P. holding 156,469 shares, or 3.0%.
Managing members Andrew J. Schwab and Dr. Kush Parmar each report beneficial ownership of 291,788 shares, representing 5.5% of the common stock, while Dr. Scott M. Rocklage reports 135,319 shares, or 2.6%. These percentages are based on 5,280,471 shares outstanding as of December 30, 2025, after an 8‑for‑1 reverse stock split effective February 2, 2026.
The filing also notes recent open‑market sales by 5AM Ventures V. On February 25, 2025, it sold 87,052 shares at prices between $6.00 and $6.15 per share, with a weighted average of $6.07. On February 26, 2025, it sold 75,000 shares at prices between $6.00 and $6.14, with a weighted average of $6.06.
Rallybio Corp Chief Financial Officer Jonathan I. Lieber reported mixed stock transactions. On February 18, 2026, he acquired 2,500 shares of Rallybio common stock as a grant or award at $0.00 per share. On February 23, 2026, he sold 789 shares of common stock at an average price of $5.06 per share, and a footnote explains this sale was made solely to cover tax withholding obligations from the vesting of a performance stock award. Following these transactions, he directly holds 4,115 shares of Rallybio common stock.